Bentley Launches BeBack Crossing Catheter to Treat Heavily Calcified Lesions

January 24, 2023—Bentley, a Germany-based company focused on the endovascular treatment of aortic and peripheral vascular disease, announced the launch of the BeBack crossing catheter, which is designed for the treatment of heavily calcified lesions. In September 2022, Bentley announced the acquisition of the GoBack catheter from Israel-based Upstream Peripheral Technologies. Upstream initially launched the device in 2019. It was available in 23 countries.

After the acquisition, GoBack was rebranded as the BeBack to benefit from Bentley’s corporate branding and product synergies. Bentley intends to extend the global availability of the BeBack device through its partner network into those countries where the company is already active with its current product portfolio. The BeBack has received CE Mark approval and FDA clearance, noted the company.

According to the company, the BeBack crossing catheter is available in both an 80- and 120-cm catheter in both 2.9- and 4-F sizes. The device features include a steerable and adjustable nitinol needle, which can be used for crossing and targeted reentry. Also, a radiopaque marker indicates the direction the curved needle protrudes from the catheter tip.

The catheter allows for multiple treatment options including antegrade, retrograde, and crossover for intraluminal or subintimal approach of stenotic or occluded lesions, stated Bentley.

In the September press release, Bentley advised that the device is being produced in Israel and initially will be shipped from there. Production will transfer to Bentley’s facility in Germany, which will be completed by 2025.